Elevation Wealth Partners’s AbbVie ABBV Stock Holding History

Elevation Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.34M	Buy	5,112 +3	+0.1%	+$769	0.38%	44
2026 Q2	$1.29M	Buy	5,109 +122	+2%	+$26.2K	0.39%	43
2026 Q1	$1.08M	Sell	4,987 -350	-7%	-$77.6K	0.39%	42
2025 Q4	$1.22M	Sell	5,337 -173	-3%	-$39.4K	0.43%	40
2025 Q3	$1.28M	Buy	5,510 +104	+2%	+$21.2K	0.46%	40
2025 Q2	$1M	Hold	5,406	–	–	0.4%	45
2025 Q1	$1.13M	Sell	5,406 -146	-3%	-$28.4K	0.49%	41
2024 Q4	$987K	Sell	5,552 -146	-3%	-$26.8K	0.42%	41
2024 Q3	$1.13M	Hold	5,698	–	–	0.48%	40
2024 Q2	$977K	Hold	5,698	–	–	0.46%	43
2024 Q1	$1.04M	Sell	5,698 -790	-12%	-$136K	0.52%	37
2023 Q4	$967K	Buy	6,488 +5,004	+337%	+$730K	0.58%	35
2023 Q3	$221K	Hold	1,484	–	–	0.19%	52
2023 Q2	$200K	Hold	1,484	–	–	0.17%	58
2023 Q1	$237K	Buy	+1,484	New	+$227K	0.22%	55

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return

Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $2.5B AUM 20.77% 1-Year Est. Return

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Elevation Wealth Partners's ABBV Position: Q3 2026 in Review

Elevation Wealth Partners increased its AbbVie (ABBV) stake by 0.06% in Q3 2026, buying an estimated $769 and bringing the position to 5,112 shares worth $1.34M. The position accounts for 0.38% of the portfolio, ranked #44.

Elevation Wealth Partners first reported a position in ABBV in Q1 2023 and has held it in 15 quarters since. 1,657 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Elevation Wealth Partners held 5,112 shares of AbbVie worth $1.34M as of Q3 2026.
Elevation Wealth Partners bought 3 AbbVie shares in Q3 2026, an estimated $769.
AbbVie made up 0.38% of Elevation Wealth Partners's portfolio in Q3 2026, its #44 holding.
Elevation Wealth Partners first reported a position in AbbVie in Q1 2023 and has held it in 15 quarters since.
1,657 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.